Shanghai Shen Lian Biomedical's (SHSE:688098) Anemic Earnings Might Be Worse Than You Think
Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) stock showed strength after its weak earnings report. While shareholders may be willing to overlook soft profit numbers, we believe that the
Express delivery of evening announcement of listed companies on December 27th
Longma Sanitation: the securities abbreviation will be changed to "Fulongma" Longma Sanitation (603686) on the evening of December 27th, and the company's securities abbreviation will be changed from "Longma Sanitation" to "Fulongma" from January 4, 2022. China Telecom Corporation: Zhu Min resigned as Executive Vice President due to job transfer China Telecom Corporation (601728) announced on the evening of December 27th that Zhu Min has resigned as Executive Director, Executive Vice President, Chief Financial Officer and Secretary of the Board of Directors due to job transfer. Botian environment: CIC innovation plans to reduce its holdings by no more than 1.
Shenlian Bio (688098.SH): shareholder UBI intends to reduce its stake by no more than 3%
688098.SH announced that as of the date of this announcement, UBI, the shareholder of the company, held a total of 62.1385 million shares of the company, accounting for 15.13% of the total shares of the company. Due to the capital needs of shareholders' own development, UBI intends to reduce its holdings of no more than 12.3193 million shares of the company, that is, no more than 3 per cent of the company's total share capital, by means of centralized bidding and block trading. The reduction period shall be within 6 months after 15 trading days from the date of disclosure of this announcement.
UBI, the main shareholder of 688098.SH, intends to reduce its holdings by no more than 3%.
Zhitong Financial APP News, Shenlian Biology (688098.SH) announced that the company's shareholders, United Biopharmaceuticals ("UBI"), intend to reduce their holdings of no more than 12.3193 million shares of the company through centralized bidding and bulk trading, that is, no more than 3 per cent of the company's total share capital.
Shenlian Biological latest announcement: 2.5 million restricted shares will be lifted
Shenlian Bio announced that the number of strategic allotment shares in circulation is 2.5 million shares, with a sales limit of 24 months. The company confirms that the number of shares in circulation is the total number of strategic allotment shares during the restricted period; the listing date of the restricted shares is October 28, 2021. According to Shenlian Biological 2021, the company's main income was 153 million yuan, down 1.03% from the same period last year; the net profit was 44.421 million yuan, down 26.88% from the same period last year; and 38.5163 million yuan was deducted from non-net profit, down 22.87% from the same period last year.